TARS2 and Combined oxidative phosphorylation defect type 21: We identified two novel TARS2 variants in our COXPD21 patients, which expands the genetic variant spectrum of TARS2. Our study suggested that TARS2 c.470 C > G is a Chinese-specific founder mutation and should be considered for inclusion in a Chinese carrier screening panel.